Skip to main content

Table 4 The relationship between the clinicopathological features and pathological complete response after neoadjuvant chemotherapy in breast cancer

From: Plasma fibrinogen acts as a predictive factor for pathological complete response to neoadjuvant chemotherapy in breast cancer: a retrospective study of 1004 Chinese breast cancer patients

 

Responder

 

Characteristics

Non-pCR (n = 879)

pCR (n = 125)

P value

Age (years)

  

0.695

  ≤ 50

497 (87.2%)

73 (12.8%)

 

  > 50

382 (88.0%)

52 (12.0%)

 

Menopausal status

  

0.241

 Pre/peri

631 (86.8%)

96 (13.2%)

 

 Post

248 (89.5%)

29 (10.5%)

 

Tumour size (cm)

  

0.006

  ≤ 5

687 (86.1%)

111 (13.9%)

 

  > 5

192 (93.2%)

14 (6.8%)

 

Lymph node involvement

  

<  0.001

 No

291 (79.7%)

74 (20.3%)

 

 Yes

588 (92.0%)

51 (8.0%)

 

Histological subtype

  

0.238

 IDC

847 (87.3%)

123 (12.7%)

 

 Non-IDC

32 (94.1%)

2 (5.9%)

 

HR status

  

<  0.001

 Positive

561 (91.5%)

52 (8.5%)

 

 Negative

318 (81.3%)

73 (18.7%)

 

HER2 statusa

  

0.215

 Positive

466 (89.3%)

56 (10.7%)

 

 Negative

370 (86.7%)

57 (13.3%)

 

Subtypea

  

<  0.001

 HR (+) HER2 (−)

338 (93.6%)

23 (6.4%)

 

 HR (+) HER2 (+)

187 (88.6%)

24 (11.4%)

 

 HR (−) HER2 (+)

187 (84.2%)

35 (15.8%)

 

 HR (−) HER2 (−)

124 (80.0%)

31 (20.0%)

 

Ki67 index (%)

  

<  0.001

  ≤ 14

253 (95.1%)

13 (4.9%)

 

  >  14

626 (84.8%)

112 (15.2%)

 

Chemotherapy cycles

  

0.689

  < 4

65 (89.0%)

8 (11.0%)

 

  ≥ 4

814 (87.4%)

117 (12.6%)

 

Fib status

  

<  0.001

 Low

635 (85.4%)

109 (14.6%)

 

 High

244 (93.9%)

16 (6.1%)

 
  1. a55 cases with unknown HER2 status and subtype
  2. Data are presented as number of cases (%)
  3. Abbreviations: pCR pathological complete response, IDC invasive ductal carcinoma, HR hormone receptor, HER2 human epidermal growth factor receptor 2, Fib fibrinogen
Back to article page